NCT02945852View on ClinicalTrials.gov

Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

November 15, 2018

Study Completion Date

May 26, 2019

Conditions
Small Cell Lung Cancer
Interventions
DRUG

apatinib

apatinib 500mg/d until progressive Disease

Trial Locations (1)

310022

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Fan Yun, MD

OTHER

NCT02945852 - Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy. | Biotech Hunter | Biotech Hunter